Skip to main content
Dr. Lal Pathlabs Limited logo

Dr. Lal Pathlabs Limited — Investor Relations & Filings

Ticker · LALPATHLAB ISIN · INE600L01024 LEI · 984500E8E9CY102B9718 BSE.NS Human health and social work activities
Open in API
Filings indexed 1,098 across all filing types
Latest filing 2025-01-30 Regulatory Filings
Country IN India
Listing BSE.NS LALPATHLAB

About Dr. Lal Pathlabs Limited

https://www.lalpathlabs.com/

Dr. Lal Pathlabs Limited is a provider of diagnostic and related healthcare tests and services. The company offers a comprehensive range of clinical laboratory tests and profiles used for prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. Its service portfolio encompasses pathology, including biochemistry, hematology, clinical pathology, histopathology, and molecular diagnostics, as well as radiology services such as X-ray, ultrasound, and CT scans. The organization operates an extensive network of laboratories, patient service centers, and pick-up points, utilizing advanced automated systems and standardized processes. Key offerings include specialized wellness packages and home sample collection. The company maintains high quality standards through international and national accreditations, serving a diverse patient base and healthcare providers with a focus on accuracy and timely reporting.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Regulatory Filings
2025-01-30 English
Financial Result Updates
Regulatory Filings
2025-01-30 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is an invitation and intimation for an earnings conference call scheduled for January 30, 2025, to discuss the Q3 and 9 months FY25 financial results of Dr. Lal PathLabs Limited. It includes details about the call, participants, dial-in numbers, and a brief company overview. There are no actual financial statements or substantive financial data presented in the document. It is a notice about the upcoming earnings call rather than the call transcript itself or the earnings release. Therefore, the document fits best into the category of Call Transcript (CT) invitation or announcement. However, since it is only an invitation and not the transcript, and given the classification options, the closest and most appropriate category is Call Transcript (CT) as it relates directly to the earnings call content. Confidence is high due to clear mention of earnings call and no financial data present.
2025-01-24 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-01-23 English
Board Meeting — Financial Results/Dividend/Other business matters
Regulatory Filings Classification · 95% confidence The document is a notice of a Board Meeting scheduled to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2024, and to consider a proposal for an interim dividend. It is an announcement informing the stock exchanges about the upcoming board meeting and related procedural details such as the trading window closure. The document does not contain actual financial results or detailed financial data, nor is it a full report. It is a regulatory announcement about a board meeting and upcoming financial disclosures. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not contain the actual report or detailed financial data.
2025-01-23 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2025-01-08 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.